Pravastatin Sodium Tablets USP are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to:
Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD.
Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. Reduce elevated serum TG levels in patients with hypertriglyceridemia.
Treat patients with primary dysbetalipoproteinemia who are not responding to diet.
Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy.
Limitations of use:
Pravastatin Sodium Tablets USP have not been studied in Fredrickson Types I and V dyslipidemias.
